Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601717 | 0.83 | HTR2C (0.70) | HTR2CHTTKITKDM4EMEN1 | |
| SCHEMBL28057522 | 0.83 | HTR2C (0.70) | HTR2CHTTKITKDM4EMEN1 | |
| SCHEMBL190521 | 0.81 | HTR2C (0.68) | HTR2CKITCYP1A2CYP3A4CLK4 | |
| SCHEMBL29360192 | 0.81 | HTR2C (0.68) | HTR2CKITCYP1A2CYP3A4CLK4 | |
| SCHEMBL4193100 | 0.79 | HTR2C (0.65) | HTR2CKITAXLMKNK1MKNK2 | |
| SCHEMBL31337089 | 0.79 | HTR2C (0.65) | HTR2CKITAXLMKNK1MKNK2 | |
| SCHEMBL12789863 | 0.79 | HTR2C (0.65) | HTR2CHTTKITMEN1KMT2A | |
| SCHEMBL13034670 | 0.79 | HTR2C (0.65) | HTR2CHTTKITALDH1A1MAPT | |
| SCHEMBL14107782 | 0.78 | HTR2C (0.63) | HTR2CHTTKITALDH1A1KDM4E | |
| SCHEMBL14083387 | 0.78 | HTR2C (0.63) | HTR2CHTTKITCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| CN-101437819-B | Pyridopyrazines and derivatives thereof as alk and c-MET inhibitors | CEPHALON INC | 2013-06-19 | — | — | CN | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8080561-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7919502-B2 | Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| EP-2013206-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006071958-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | HTR2C 806/4885HTT 3168/4885KIT 37/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | HTR2C 954/4885HTT 693/4885KIT 2117/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | HTR2C 954/4885HTT 693/4885KIT 2117/4885 |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, CDK1 | HTR2C 686/4885HTT 3384/4885KIT 1378/4885 |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | HTR2C 2702/4885HTT 4804/4885KIT 128/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | HTR2C 806/4885HTT 3168/4885KIT 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.